Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Lonsurf 15 mg/6.14 mg film-coated tablets, Relatlimab + Nivolumab Fixed Dose Combination (FDC), Lonsurf 20 mg/8.19 mg film-coated tablets, Stivarga 40 mg film-coated tablets
Bristol-Myers Squibb Australia Pty Ltd
Metastatic Colorectal Cancer
1 trial -
Loperamide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diarrhea-predominant Irritable Bowel Syndrome
1 trial -
Loperamide
Chengdu University of Traditional Chinese Medicine
Diarrhea-predominant Irritable Bowel Syndrome
1 trial -
Lorundrostat Placebo Tablets, Lorundrostat, Synacthen 0,25 mg/ml Injektionslösung, Lorundrostat
Mineralys Therapeutics
Uncontrolled and Resistant Hypertension
1 trial -
Lorundrostat, Lorundrostat, Synacthen 0,25 mg/ml Injektionslösung, Lorundrostat Placebo tablet, Lorundrostat
Mineralys Therapeutics
Hypertension
1 trial -
Losmapimod oral tablet
Fulcrum Therapeutics
COVID-19
1 trial -
Low-dose complex B-vitamins
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hyperhomocysteinemia
1 trial -
Lubiprostone
Takeda
Irritable Bowel Syndrome With Constipation
1 trial -
Lynparza 100 mg film-coated tablets, ABIRATERONE , PREDNISOLONE , Lynparza 150 mg film-coated tablets
AstraZeneca AB
Metastatic castration-resistant prostate cancer
1 trial -
Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets
The George Institute
Patients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases
1 trial -
Lynparza 100 mg film-coated tablets, Placebo - film-coated tablets, Lynparza 150 mg film-coated tablets
AstraZeneca AB
Breast Cancer
1 trial -
Lynparza 100 mg film-coated tablets, Sodium Chloride Intravenous Infusion BP 0.9% w/v Solution for Infusion (not authorised), Placebo film-coated tablet (Not Authorised), Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, BEVACIZUMAB
AstraZeneca AB
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer
1 trial -
Lynparza 150 mg film-coated tablets, IBRANCE 125 mg hard capsules, Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Tabrecta 200 mg film-coated tablets, Daurismo 100 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, Tabrecta 150 mg film-coated tablets, Lytgobi 4 mg film-coated tablets, Mekinist 2 mg film-coated tablets, IBRANCE 100 mg hard capsules, Tyverb 250 mg film-coated tablets, Tafinlar 75 mg hard capsules, Zykadia 150 mg hard capsules, IBRANCE 7
The George Institute
Unresectable locally advanced and/or metastatic soft-tissue sarcoma
1 trial -
Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets
AstraZeneca AB
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, prostate cancer, endometrium cancer
1 trial -
Lynparza 150 mg film-coated tablets, PACLITAXEL , CARBOPLATIN , GEMCITABINE , DOXORUBICIN , Lynparza 100 mg film-coated tablets, CISPLATIN , BEVACIZUMAB
Fondazione Telethon ETS
Recurrent ovarian cancer
1 trial -
MEDI4736 Placebo, DURVALUMAB
CERO THERAPEUTICS HOLDINGS, INC.
Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients
1 trial -
MEDROXYPROGESTERONE , Opevesostat, EXEMESTANE , LETROZOLE , MEGESTROL , FLUDROCORTISONE , TAMOXIFEN , FULVESTRANT , HYDROCORTISONE , DEXAMETHASONE
Merck Sharp and Dohme
Breast cancer, Ovarian cancer, Endometrial cancer
1 trial -
MESNA, MESNA, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan 1000 mg milteliai injekciniam tirpalui, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cycloph
Iovance Biotherapeutics B.V.
Melanoma
1 trial -
METFORMIN
Pari Pharma GmbH
Type 2 Diabetes complete remission after bariatric surgery under antidiabetic drug
1 trial -
METFORMIN, COLCHICINE, MINOCYCLINE, Placebo tablets are identical to active minocycline tablets and will be relabelled identical to the study drug. Placebo tablets will have the same composition, except for the active substance. (microcrystalline cellulose, magnesium stearate).
Disc Medicine
PASC: post-acute sequelae of SARS-CoV-2 infection
1 trial -
METFORMINE ARROW LAB 1000 mg, comprimé pelliculé sécable, Placebo de metformine Arrow Lab 1000 mg - Composition: Cellulose microcristalline; Lactose monohydraté; Stéarate de magnésium (vegetable origin); Opadry TM 07F28588; Eau purifiée
Pari Pharma GmbH
Vascular calcification and type 1 diabetes
1 trial -
METHOTREXATE, DEXAMETHASONE, DEXAMETHASONE, CYTARABINE, CYTARABINE, DASATINIB, PREDNISOLONE, CYTARABINE, PONATINIB, CYTARABINE, METHOTREXATE, METHOTREXATE, VINCRISTINE SULFATE, PREDNISOLONE, IMATINIB MESILATE, METHOTREXATE, DEXAMETHASONE, Olverembatinib, DEXAMETHASONE, VINCRISTINE SULFATE, DEXAMETHASONE, DASATINIB, DEXAMETHASONE
Lacuna Pharma Pty Ltd
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
1 trial -
METHOTREXATE, Dazukibart, AZATHIOPRINE, HYDROCORTISONE, DEXAMETHASONE, METHYLPREDNISOLONE, CHLOROQUINE PHOSPHATE, MYCOPHENOLATE MOFETIL, BETAMETHASONE, METHYLPREDNISOLONE, PREDNISOLONE, TRIAMCINOLONE ACETONIDE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, DEFLAZACORT, BETAMETHASONE, PREDNISONE, BUDESONIDE, METHOTREXATE
Pfizer Australia Pty Ltd
Idiopathic Inflammatory Myopathy (including dermatomyositis or polymyositis)
1 trial -
METHOTREXATE, LENALIDOMIDE, LENALIDOMIDE
Pari Pharma GmbH
Cutaneous lupus erythematosus
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources